Back to Results
First PageMeta Content
Myopathy / Myotubularin 1 / Weakness / Gene delivery / Emerging technologies / Medical genetics / Medical research / Centronuclear myopathy / Biology / Health / Medicine


Microsoft Word - Audentes PR ASGCT 11MAY15 FIN.docx
Add to Reading List

Document Date: 2015-05-12 13:57:54

Open Document

File Size: 101,64 KB

Share Result on Facebook

City

Gainesville / New Orleans / SAN FRANCISCO / Evry / /

Company

Genethon / Audentes / Therapeutics Inc. / /

Country

France / /

/

Event

Business Partnership / /

Facility

University of Florida / College of Medicine / University of Washington School / /

IndustryTerm

gene therapy technology / biotechnology / gene therapy products / treatment of Pompe Disease / manufacturing / energy / /

MedicalCondition

AAV Therapy Attenuates Respiratory Dysfunction / progressive muscle weakness / Hemophilia B / Pompe Disease Pompe Disease / Myotubular Myopathy / severe muscle weakness / disorder / serious / rare diseases / orphan genetic diseases / eye diseases / Pompe Disease / /

MedicalTreatment

gene therapy / enzyme replacement therapy / /

Organization

University of Washington / University of Florida / /

Person

Gray / Mack / Patterson / Todd / /

Position

Investigator / Vice President of Research and Development / President and Chief Executive Officer / Suite Executive / /

Product

AT002 / AT001 / /

ProvinceOrState

Louisiana / Florida / /

Technology

Gene Therapy / alpha / Cell Therapy / biotechnology / AAV gene therapy technology / Gene Delivery / /

URL

www.audentestx.com / www.genethon.fr / http /

SocialTag